{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:50:41Z","timestamp":1795132241000,"version":"4.10.3"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41409-026-02922-0","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:29:01Z","timestamp":1780421341000},"page":"1015-1023","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-5803","authenticated-orcid":false,"given":"Esteban","family":"Arrieta-Bola\u00f1os","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-7060","authenticated-orcid":false,"given":"Alberto Cardoso Martins","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3451-3624","authenticated-orcid":false,"given":"Marco","family":"Andreani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-0002","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-143X","authenticated-orcid":false,"given":"Neema P.","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-544X","authenticated-orcid":false,"given":"Rohtesh S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-0628","authenticated-orcid":false,"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Petersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5908-0792","authenticated-orcid":false,"given":"Simona","family":"Piemontese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-8084","authenticated-orcid":false,"given":"Nicole","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-2981","authenticated-orcid":false,"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Spellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5519-9154","authenticated-orcid":false,"given":"Isabel","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5827-8000","authenticated-orcid":false,"given":"Katharina","family":"Fleischhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-2765","authenticated-orcid":false,"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2922_CR1","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","volume":"110","author":"SJ Lee","year":"2007","unstructured":"Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576\u201383.","journal-title":"Blood"},{"key":"2922_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood.2019001212","volume":"134","author":"J Dehn","year":"2019","unstructured":"Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, et al. Selection of Unrelated Donors and Cord Blood Units for Hematopoietic Cell Transplantation: Guidelines from NMDP\/CIBMTR. Blood. 2019;134:924\u201334. https:\/\/doi.org\/10.1182\/blood.2019001212.","journal-title":"Blood"},{"key":"2922_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transpl. 2025;60:519\u201328. https:\/\/doi.org\/10.1038\/s41409-025-02524-2.","journal-title":"Bone Marrow Transpl"},{"key":"2922_CR4","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"2922_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","volume":"58","author":"I Yakoub-Agha","year":"2023","unstructured":"Yakoub-Agha I, Greco R, Onida F, de la Camara R, Ciceri F, Corbacioglu S, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transpl. 2023;58:696\u2013700.","journal-title":"Bone Marrow Transpl"},{"key":"2922_CR6","doi-asserted-by":"publisher","first-page":"D1053","DOI":"10.1093\/nar\/gkac1011","volume":"51","author":"DJ Barker","year":"2023","unstructured":"Barker DJ, Maccari G, Georgiou X, Cooper MA, Flicek P, Robinson J, et al. The IPD-IMGT\/HLA Database. Nucleic Acids Res. 2023;51:D1053\u2013D60.","journal-title":"Nucleic Acids Res"},{"key":"2922_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/tan.13811","volume":"95","author":"CK Hurley","year":"2020","unstructured":"Hurley CK, Kempenich J, Wadsworth K, Sauter J, Hofmann JA, Schefzyk D, et al. Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0. HLA. 2020;95:516\u201331.","journal-title":"HLA"},{"key":"2922_CR8","first-page":"1139","volume":"30","author":"P Kongtim","year":"2024","unstructured":"Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro RM, et al. ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies. Transpl Cell Ther. 2024;30:1139\u201354.","journal-title":"Transpl Cell Ther"},{"key":"2922_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3324\/haematol.2012.077685","volume":"98","author":"A Ruggeri","year":"2013","unstructured":"Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d\u2019Histocompatibilite et d\u2019Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. Haematologica. 2013;98:1154\u201360.","journal-title":"Haematologica"},{"key":"2922_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/tan.14277","volume":"97","author":"ACM Lima","year":"2021","unstructured":"Lima ACM, Bonfim C, Getz J, Dornelles LN, do Amaral GB, Petterle RR, et al. The impact of donor-specific anti-human leukocyte antigen antibodies in salvage haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide in patients with nonmalignant disorders. HLA. 2021;97:493\u2013504.","journal-title":"HLA"},{"key":"2922_CR11","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/s41375-025-02724-1","volume":"39","author":"J Schetelig","year":"2025","unstructured":"Schetelig J, Baldauf H, Rave C, Bug G, Muller LP, Wagner-Drouet EM, et al. Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings. Leukemia. 2025;39:2523\u201332.","journal-title":"Leukemia"},{"key":"2922_CR12","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41375-024-02359-8","volume":"38","author":"S Piemontese","year":"2024","unstructured":"Piemontese S, Labopin M, Choi G, Broers AEC, Peccatori J, Meijer E, et al. Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide. Leukemia. 2024;38:2016\u201322. https:\/\/doi.org\/10.1038\/s41375-024-02359-8.","journal-title":"Leukemia"},{"key":"2922_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","volume":"11","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018;11:40 https:\/\/doi.org\/10.1186\/s13045-018-0586-4.","journal-title":"J Hematol Oncol"},{"key":"2922_CR14","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1200\/JCO.20.03502","volume":"39","author":"BE Shaw","year":"2021","unstructured":"Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021;39:1971\u201382.","journal-title":"J Clin Oncol"},{"key":"2922_CR15","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1200\/JCO-25-00206","volume":"43","author":"SJ Lee","year":"2025","unstructured":"Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, et al. Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation. J Clin Oncol. 2025;43:3369\u201380.","journal-title":"J Clin Oncol"},{"key":"2922_CR16","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1182\/bloodadvances.2024013756","volume":"8","author":"SR Spellman","year":"2024","unstructured":"Spellman SR, Sparapani R, Maiers M, Shaw BE, Laud P, Bupp C, et al. Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes. Blood Adv. 2024;8:6082\u20137.","journal-title":"Blood Adv"},{"key":"2922_CR17","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1182\/blood.2023023697","volume":"143","author":"J Sanz","year":"2024","unstructured":"Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, et al. Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT. Blood. 2024;143:2534\u201343.","journal-title":"Blood"},{"key":"2922_CR18","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/bloodadvances.2023012133","volume":"8","author":"J Sanz","year":"2024","unstructured":"Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8:2332\u201341.","journal-title":"Blood Adv"},{"key":"2922_CR19","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41409-021-01289-8","volume":"56","author":"S Seo","year":"2021","unstructured":"Seo S, Usui Y, Matsuo K, Atsuta Y, Igarashi A, Fukuda T, et al. Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. Bone Marrow Transpl. 2021;56:2410\u201322.","journal-title":"Bone Marrow Transpl"},{"key":"2922_CR20","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/bloodadvances.2024012669","volume":"8","author":"RS Mehta","year":"2024","unstructured":"Mehta RS, Petersdorf EW, Spellman SR, Lee SJ. Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes. Blood Adv. 2024;8:2235\u201342.","journal-title":"Blood Adv"},{"key":"2922_CR21","doi-asserted-by":"crossref","unstructured":"Mehta RS, Petersdorf EW, Wang T, Spellman SR, Lee SJ. Interplay between donor age and HLA-DP matching in 10\/10 HLA-matched unrelated donor HCT. Blood Adv. 2024;8:5438\u201349.","DOI":"10.1182\/bloodadvances.2024013677"},{"key":"2922_CR22","doi-asserted-by":"crossref","unstructured":"Sanz J, Ferhat AT, Kulagin A, Kroger N, Rovira M, Lazzari L, et al. Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2025;111:981\u201389.","DOI":"10.3324\/haematol.2025.289110"},{"key":"2922_CR23","doi-asserted-by":"crossref","unstructured":"Mehta RS, Sparapani RA, Kanakry CG, McCurdy SR, Saultz J, Lazaryan A, et al. Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis. JAMA Oncol. 2025;12:28\u201337.","DOI":"10.1001\/jamaoncol.2025.4551"},{"key":"2922_CR24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487\u201396.","journal-title":"N Engl J Med"},{"key":"2922_CR25","doi-asserted-by":"crossref","unstructured":"Rocha V, Labopin M, Raiola AM, Devillier R, Bramanti S, Ciceri F, et al. Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMT. Bone Marrow Transpl. 2026;61:75\u201381.","DOI":"10.1038\/s41409-025-02735-7"},{"key":"2922_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41409-025-02742-8","volume":"61","author":"G Battipaglia","year":"2026","unstructured":"Battipaglia G, Wehr C, Admiraal R, Nierkens S, Malard F, Zeiser R, et al. Usage of rabbit anti-thymocyte \/ anti-T-lymphocyte globulins (ATG \/ ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Bone Marrow Transpl. 2026;61:128\u201341. https:\/\/doi.org\/10.1038\/s41409-025-02742-8.","journal-title":"Bone Marrow Transpl"},{"key":"2922_CR27","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"I Walker","year":"2020","unstructured":"Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7:e100\u2013e11.","journal-title":"Lancet Haematol"},{"key":"2922_CR28","doi-asserted-by":"crossref","unstructured":"Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bolanos-Meade J, Abboud R, et al. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. J Clin Oncol. 2024;42:3277\u201386.","DOI":"10.1200\/JCO.24.00184"},{"key":"2922_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2016.151779","volume":"102","author":"A Ruggeri","year":"2017","unstructured":"Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017;102:401\u201310.","journal-title":"Haematologica"},{"key":"2922_CR30","doi-asserted-by":"crossref","unstructured":"Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, et al. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation. J Clin Oncol. 2025;43:2772\u201381.","DOI":"10.1200\/JCO-25-00856"},{"key":"2922_CR31","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/JCO.20.01086","volume":"39","author":"B Watkins","year":"2021","unstructured":"Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021;39:1865\u201377.","journal-title":"J Clin Oncol"},{"key":"2922_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kroger","year":"2016","unstructured":"Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374:43\u201353.","journal-title":"N Engl J Med"},{"key":"2922_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855\u201364.","journal-title":"Lancet Oncol"},{"key":"2922_CR34","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017;35:4003\u201311.","journal-title":"J Clin Oncol"},{"key":"2922_CR35","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1182\/blood-2014-09-599241","volume":"126","author":"L Pascal","year":"2015","unstructured":"Pascal L, Tucunduva L, Ruggeri A, Blaise D, Ceballos P, Chevallier P, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Blood. 2015;126:1027\u201332. https:\/\/doi.org\/10.1182\/blood-2014-09-599241.","journal-title":"Blood"},{"key":"2922_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa2503189","volume":"393","author":"DJ Curtis","year":"2025","unstructured":"Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, et al. Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. N Engl J Med. 2025;393:243\u201354.","journal-title":"N Engl J Med"},{"key":"2922_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood.2019000487","volume":"134","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia G, Labopin M, Kroger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892\u20139.","journal-title":"Blood"},{"key":"2922_CR38","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1200\/JCO.24.00582","volume":"42","author":"E Arrieta-Bolanos","year":"2024","unstructured":"Arrieta-Bolanos E, Bonneville EF, Crivello P, Robin M, Gedde-Dahl T, Salmenniemi U, et al. Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2024;42:3287\u201399.","journal-title":"J Clin Oncol"},{"key":"2922_CR39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41409-024-02219-0","volume":"59","author":"B Meissner","year":"2024","unstructured":"Meissner B, Lang P, Bader P, Hoenig M, Muller I, Meisel R, et al. Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression. Bone Marrow Transpl. 2024;59:587\u201396.","journal-title":"Bone Marrow Transpl"},{"key":"2922_CR40","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/S2352-3026(17)30104-7","volume":"4","author":"M Eapen","year":"2017","unstructured":"Eapen M, Wang T, Veys PA, Boelens JJ, St Martin A, Spellman S, et al. Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematol. 2017;4:e325\u2013e33. https:\/\/doi.org\/10.1016\/S2352-3026(17)30104-7.","journal-title":"Lancet Haematol"},{"key":"2922_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/bjh.13267","volume":"169","author":"L Tucunduva","year":"2015","unstructured":"Tucunduva L, Volt F, Cunha R, Locatelli F, Zecca M, Yesilipek A, et al. Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases. Br J Haematol. 2015;169:103\u201310. https:\/\/doi.org\/10.1111\/bjh.13267.","journal-title":"Br J Haematol"},{"key":"2922_CR42","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","volume":"33","author":"C Peters","year":"2015","unstructured":"Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"2922_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021;39:295\u2013307.","journal-title":"J Clin Oncol"},{"key":"2922_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood.2023021336","volume":"143","author":"P Merli","year":"2024","unstructured":"Merli P, Algeri M, Galaverna F, Bertaina V, Lucarelli B, Boccieri E, et al. TCRalphabeta\/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood. 2024;143:279\u201389.","journal-title":"Blood"},{"key":"2922_CR45","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3324\/haematol.2024.285345","volume":"109","author":"A Ruggeri","year":"2024","unstructured":"Ruggeri A, Santoro N, Galimard JE, Kalwak K, Algeri M, Zubarovskaya L, et al. Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study. Haematologica. 2024;109:2122\u201330.","journal-title":"Haematologica"},{"key":"2922_CR46","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41409-025-02720-0","volume":"60","author":"BE Di Majo","year":"2025","unstructured":"Di Majo BE, Abouqateb M, Galimard JE, Dalissier A, Lucchini G, Versluys B, et al. Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP. Bone Marrow Transpl. 2025;60:1635\u201341.","journal-title":"Bone Marrow Transpl"},{"key":"2922_CR47","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/hematology.2019000056","volume":"2019","author":"A Ruggeri","year":"2019","unstructured":"Ruggeri A. Optimizing cord blood selection. Hematol Am Soc Hematol Educ Program. 2019;2019:522\u201331. https:\/\/doi.org\/10.1182\/hematology.2019000056.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2922_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1182\/blood-2013-05-506253","volume":"123","author":"M Eapen","year":"2014","unstructured":"Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133\u201340. https:\/\/doi.org\/10.1182\/blood-2013-05-506253.","journal-title":"Blood"},{"key":"2922_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/stcltm\/szac079","volume":"12","author":"J Kurtzberg","year":"2023","unstructured":"Kurtzberg J, Troy JD, Page KM, El Ayoubi HR, Volt F, Maria Scigliuolo G, et al. Unrelated Donor Cord Blood Transplantation in Children: Lessons Learned Over 3 Decades. Stem Cells Transl Med. 2023;12:26\u201338.","journal-title":"Stem Cells Transl Med"},{"key":"2922_CR50","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1200\/JCO.20.03643","volume":"39","author":"NP Mayor","year":"2021","unstructured":"Mayor NP, Wang T, Lee SJ, Kuxhausen M, Vierra-Green C, Barker DJ, et al. Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. J Clin Oncol. 2021;39:2397\u2013409.","journal-title":"J Clin Oncol"},{"key":"2922_CR51","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1182\/blood-2013-10-532671","volume":"123","author":"MA Fernandez-Vina","year":"2014","unstructured":"Fernandez-Vina MA, Wang T, Lee SJ, Haagenson M, Aljurf M, Askar M, et al. Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood. 2014;123:1270\u20138.","journal-title":"Blood"},{"key":"2922_CR52","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S2352-3026(19)30208-X","volume":"7","author":"EW Petersdorf","year":"2020","unstructured":"Petersdorf EW, Carrington M, O\u2019HUigin C, Bengtsson M, De Santis D, Dubois V, et al. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol. 2020;7:e50\u2013e60.","journal-title":"Lancet Haematol"},{"key":"2922_CR53","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood-2017-03-742346","volume":"130","author":"K Fleischhauer","year":"2017","unstructured":"Fleischhauer K, Shaw BE. HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities. Blood. 2017;130:1089\u201396.","journal-title":"Blood"},{"key":"2922_CR54","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood.2022015708","volume":"140","author":"E Arrieta-Bolanos","year":"2022","unstructured":"Arrieta-Bolanos E, Crivello P, He M, Wang T, Gadalla SM, Paczesny S, et al. A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation. Blood. 2022;140:659\u201363.","journal-title":"Blood"},{"key":"2922_CR55","first-page":"74.e1","volume":"32","author":"SR McCurdy","year":"2026","unstructured":"McCurdy SR, Solomon SR, Shaffer BC, He M, Bolon YT, Blouin AG, et al. Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation. Transpl Cell Ther. 2026;32:74.e1\u2013e14.","journal-title":"Transpl Cell Ther"},{"key":"2922_CR56","doi-asserted-by":"publisher","first-page":"e920","DOI":"10.1097\/HS9.0000000000000920","volume":"7","author":"MA Kharfan-Dabaja","year":"2023","unstructured":"Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, et al. Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT. Hemasphere. 2023;7:e920.","journal-title":"Hemasphere"},{"key":"2922_CR57","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMoa0811036","volume":"361","author":"L Vago","year":"2009","unstructured":"Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478\u201388.","journal-title":"N Engl J Med"},{"key":"2922_CR58","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","volume":"11","author":"S Pagliuca","year":"2024","unstructured":"Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, et al. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11:e448\u2013e58.","journal-title":"Lancet Haematol"},{"key":"2922_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86252","volume":"1","author":"CG Kanakry","year":"2016","unstructured":"Kanakry CG, Coffey DG, Towlerton AM, Vulic A, Storer BE, Chou J, et al. Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight. 2016;1:e86252.","journal-title":"JCI Insight"},{"key":"2922_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2021015129","volume":"141","author":"J Rimando","year":"2023","unstructured":"Rimando J, McCurdy SR, Luznik L. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023;141:49\u201359.","journal-title":"Blood"},{"key":"2922_CR61","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1200\/JCO-24-01303","volume":"42","author":"R Chakraverty","year":"2024","unstructured":"Chakraverty R. How Important Is Unrelated Donor Human Leukocyte Antigen Disparity in the Post-Transplant Cyclophosphamide Era? J Clin Oncol. 2024;42:3263\u20135.","journal-title":"J Clin Oncol"},{"key":"2922_CR62","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1159\/000547767","volume":"148","author":"AT Turki","year":"2025","unstructured":"Turki AT, Mussetti A, Scheidler KM, Kehrmann J, Crivello P, Hosch R, et al. Artificial Intelligence in Hematopoietic Stem Cell Transplantation Care and Complication Management. Acta Haematol. 2025;148:527\u201345.","journal-title":"Acta Haematol"},{"key":"2922_CR63","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","volume":"13","author":"K Fleischhauer","year":"2012","unstructured":"Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;13:366\u201374.","journal-title":"Lancet Oncol"},{"key":"2922_CR64","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1182\/blood-2014-05-576041","volume":"124","author":"J Pidala","year":"2014","unstructured":"Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014;124:2596\u2013606.","journal-title":"Blood"},{"key":"2922_CR65","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.20.00265","volume":"38","author":"EW Petersdorf","year":"2020","unstructured":"Petersdorf EW, Bengtsson M, De Santis D, Dubois V, Fleischhauer K, Gooley T, et al. Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation. J Clin Oncol. 2020;38:2712\u20138.","journal-title":"J Clin Oncol"},{"key":"2922_CR66","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood-2017-08-801449","volume":"131","author":"S Morishima","year":"2018","unstructured":"Morishima S, Shiina T, Suzuki S, Ogawa S, Sato-Otsubo A, Kashiwase K, et al. Evolutionary basis of HLA-DPB1 alleles affects acute GVHD in unrelated donor stem cell transplantation. Blood. 2018;131:808\u201317.","journal-title":"Blood"},{"key":"2922_CR67","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2014-09-599969","volume":"124","author":"EW Petersdorf","year":"2014","unstructured":"Petersdorf EW, Gooley TA, Malkki M, Bacigalupo AP, Cesbron A, Du Toit E, et al. HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. Blood. 2014;124:3996\u20134003.","journal-title":"Blood"},{"key":"2922_CR68","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1182\/blood.2022015860","volume":"139","author":"EW Petersdorf","year":"2022","unstructured":"Petersdorf EW, Bengtsson M, Horowitz M, McKallor C, Spellman SR, Spierings E, et al. HLA-DQ heterodimers in hematopoietic cell transplantation. Blood. 2022;139:3009\u201317.","journal-title":"Blood"},{"key":"2922_CR69","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2006-06-032193","volume":"109","author":"JA Wade","year":"2007","unstructured":"Wade JA, Hurley CK, Takemoto SK, Thompson J, Davies SM, Fuller TC, et al. HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood. 2007;109:4064\u201370.","journal-title":"Blood"},{"key":"2922_CR70","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.bbmt.2008.07.001","volume":"14","author":"R Duquesnoy","year":"2008","unstructured":"Duquesnoy R, Spellman S, Haagenson M, Wang T, Horowitz MM, Oudshoorn M. HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transpl. 2008;14:1064\u201371.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2922_CR71","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bbmt.2011.09.008","volume":"18","author":"S Spellman","year":"2012","unstructured":"Spellman S, Klein J, Haagenson M, Askar M, Baxter-Lowe LA, He J, et al. Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2012;18:739\u201346.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2922_CR72","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/bmt.2016.142","volume":"51","author":"SR Marino","year":"2016","unstructured":"Marino SR, Lee SM, Binkowski TA, Wang T, Haagenson M, Wang HL, et al. Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transpl. 2016;51:1342\u20139.","journal-title":"Bone Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02922-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02922-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02922-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:02:24Z","timestamp":1785844944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02922-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02922-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RSM reports Consultancy for OrcaBio and expert opinion for Lumanity. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}